High Content Imaging and 3D Cultures

Our state-of-the-art ImageXpress® Micro Confocal (IXM-C) High Content Imaging platform provides multi-dimensional, High-throughput Screening solutions to facilitate compound profiling, MOA analysis and; through the use of highly relevant in vitro models, to support interrogation of compound safety.

High Content Imaging

The IXM-C allows our scientists to capture high content imaging with a wide range of objective lenses, and the possibility to multiplex up to 5 wavelengths together with transmitted light. The high content imaging mode options of widefield and confocal provide the sensitivity and resolution required for a given assay. Combined with MetaXpress® High-Content Power Core Image Acquisition and Analysis Software, the ImageXpress® Micro Confocal system provides a complete multi-dimensional, high-throughput screening solution.

High Content Screening

3D cultures more closely resemble the in vivo tissue environment due to the promotion of cell-cell contacts, re-establishment of cell polarity and the production of extracellular matrices. At Sygnature Discovery we offer expertise in the high content multi-parametric imaging/screening of 3D cell cultures using the IXM-C platform for the evaluation of compound dependent effects on a number of clinically relevant parameters.

A range of assay formats are available and are applicable to multiple phases of the drug discovery process, including target identification, hit validation and candidate drug profiling.

Current assays available include:

Examples include:

Viability, cytotoxicity, phospholipidosis, mitochondrial toxicity

Mitochondrial Depolarisation:

Chlorpromazine - Mitochondrial membrane depolarisation

Neurite Dynamics:

MicroConfocal Neurite Outgrowth Assay - PC12 Neuronal cells in absense or presense of NGF Co-Culture of Endothelial cells and Normal Human Dermal Fibroblasts

Latest News

View All

First patients dosed in Phase 1a clinical…

Sygnature Discovery Appoints Industry Leaders To Board…

Sygnature Discovery invests £3.75M in Compound Management…

Sygnature Discovery collaborates with Axol Bioscience to…